Drug intelligence / Profile preview

ABA

Development stage: Preclinical
Lead developer: ARTBIO
Modality: Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ABA is an alpha radioligand therapy (ART) currently in the discovery stage of development by ARTBIO for the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. The therapeutic candidate utilizes the alpha-emitting isotope Lead-212 (212Pb) conjugated to a targeting ligand whose molecular target remains undisclosed. By targeting specific markers on cancer cells, ABA is designed to deliver high-LET (linear energy transfer) alpha radiation, which induces complex double-strand DNA breaks, leading to cell death while minimizing exposure to surrounding healthy tissues.

Other names: ABA-ARTBIO

Beyond the preview

Go deeper on ABA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABA.

Explore the full profile